AstraZeneca's Imfinzi Fails in Late-stage Trial to Treat Certain Type of Lung Cancer

HEALTH - REUTERS - AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.

Imfinzi is a human monoclonal antibody, which works to block a tumor's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response, offering an alternative to chemotherapy.

Read Also: Kalbe Farma (KLBF) Launches Serplulimab Product for Lung Cancer Patients